| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GST2; GTA2; GTH2; GSTA2-2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human GSTA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MIF4GD抗体的假设性文献示例(注：MIF4GD相关研究较为小众，以下内容为模拟参考，建议结合具体研究领域进一步核实)：
1. **"Structural characterization of MIF4GD-specific antibodies and their role in autoimmune disease modulation"**
*作者：Zhang L, et al. (2020)*
*摘要*：本研究报道了一种靶向MIF蛋白四聚体结构域(MIF4GD)的单克隆抗体的开发，通过X射线晶体学解析了抗体-抗原复合物结构，并证明该抗体可抑制MIF与CD74受体的结合，减轻实验性关节炎模型的炎症反应。
2. **"A novel anti-MIF4GD antibody inhibits tumor angiogenesis in glioblastoma models"**
*作者：Smith J, et al. (2018)*
*摘要*：文章描述了一种针对MIF4GD表位的人源化抗体，通过阻断MIF介导的血管内皮生长因子(VEGF)信号通路，显著抑制胶质母细胞瘤小鼠模型中的肿瘤血管生成和生长。
3. **"MIF4GD-specific nanobodies as potential therapeutics for sepsis-associated cytokine storm"**
*作者：Wang Y, et al. (2021)*
*摘要*：研究团队利用骆驼源纳米抗体库筛选出高亲和力MIF4GD结合剂，实验显示其能中和MIF的促炎活性，在脓毒症模型中降低IL-6、TNF-α等细胞因子水平，改善生存率。
4. **"Epitope mapping of MIF4GD reveals conformational dynamics critical for antibody recognition"**
*作者：Kumar R, et al. (2019)*
*摘要*：通过氢-氘交换质谱(HDX-MS)和定点突变分析，揭示了MIF四聚体结构域的动态构象变化，并鉴定出抗体结合的关键氨基酸残基，为优化诊断/治疗性抗体提供理论依据。
**提示**：以上为基于MIF研究的合理推测，实际文献需通过PubMed、Web of Science等平台以关键词“MIF antibody”、“MIF tetramerization domain”或“MIF structural epitope”进一步检索确认。若研究方向涉及特定疾病(如癌症、风湿病)，可结合“MIF + [疾病名称] + antibody”细化查询。
MIF4GD antibody targets macrophage migration inhibitory factor (MIF), a multifunctional cytokine involved in inflammation, immune regulation, and cancer progression. MIF is secreted by immune cells, endothelial cells, and tumor-associated cells, acting through receptors like CD74 and CXCRs to activate downstream signaling pathways (e.g., MAPK, PI3K/Akt). It promotes pro-inflammatory responses, cell proliferation, and angiogenesis while inhibiting apoptosis. Dysregulated MIF expression is linked to autoimmune diseases (e.g., rheumatoid arthritis), sepsis, and cancers, making it a therapeutic target.
The MIF4GD antibody specifically recognizes an epitope within the MIF protein, often used to neutralize its activity or detect expression in research. Studies utilize this antibody to investigate MIF's role in disease mechanisms, evaluate its inhibition in preclinical models, or validate diagnostic biomarkers. Its application spans immunoblotting, immunohistochemistry, and functional assays to block MIF-CD74 interactions. Recent research explores MIF4GD's potential in combination therapies, particularly in cancers where MIF-driven pathways confer resistance to conventional treatments. As MIF inhibitors advance into clinical trials, this antibody remains a critical tool for elucidating MIF's complex biology and therapeutic targeting.
×
